Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry

다국어 초록 (Multilingual Abstract)

Purpose A prior history of breast cancer is a risk factor for the subsequent development of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancers. This study aimed to estimate the incidence of secondary POFT malignancy in breast cancer patients and the clinical outcomes of primary and secondary POFT cancer.Materials and Methods We searched the Korea Central Cancer Registry to find patients with primary and secondary POFT cancer who had breast cancer in 1999-2017. The incidence rate and standardized incidence ratio were calculated. Additionally, we compared the overall survival of patients with primary and secondary POFT cancer.Results Based on the age-standardized rate, the incidence of second primary POFT cancer after breast cancer was 0.0763 per 100,000 women, which increased in Korea between 1999 and 2017. Among the 30,366 POFT cancer patients, 25,721 were primary POFT cancer only, and 493 had secondary POFT cancer after a breast cancer diagnosis. Second primary POFT cancer patients were older at the time of diagnosis (55 vs. 53, p < 0.001) and had a larger proportion of serous histology (68.4% vs. 51.2%, p < 0.001) than patients with primary POFT. There were no differences between the two groups in tumor stage at diagnosis. The 5-year overall survival rates were 60.2% and 56.3% for primary and secondary POFT cancer, respectively (p=0.216).Conclusion The incidence of second primary POFT cancer after breast cancer increased in Korea between 1999 and 2017. Besides, second primary POFT cancer patients were diagnosed at older ages and had more serous histology.

참고문헌 (Reference)

1 Metcalfe KA, "The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers" 96 : 222-226, 2005

2 Hall HI, "Second primary ovarian cancer among women diagnosed previously with cancer" 10 : 995-999, 2001

3 Lim MC, "Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer : a retrospective study" 18 : 800-, 2018

4 Young JL Jr, "SEER summary staging manual 2000: codes and coding instructions" National Cancer Institute 2001

5 Mellemkjaer L, "Risk of second cancer among women with breast cancer" 118 : 2285-2292, 2006

6 Kauff ND, "Risk of ovarian cancer in BRCA1 and BRCA2mutation-negative hereditary breast cancer families" 97 : 1382-1384, 2005

7 Schaapveld M, "Risk of new primary nonbreast cancers after breast cancer treatment : a Dutch population-based study" 26 : 1239-1246, 2008

8 Lakhani SR, "Pathology of ovarian cancers in BRCA1 and BRCA2 carriers" 10 : 2473-2481, 2004

9 Prior P, "Multiple primary cancers of the breast and ovary" 44 : 628-636, 1981

10 Fritz A, "International classification of diseases for oncology (ICD-O)" World Health Organization 2013

11 신원교, "Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999–2016: a retrospective study based on the Korean National Cancer Incidence Database" 대한부인종양학회 31 (31): 1-9, 2020

12 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015" 대한부인종양학회 30 (30): 1-8, 2019

13 Choi DH, "Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients" 22 : 1638-1645, 2004

14 Pennington KP, "Hereditary ovarian cancer : beyond the usual suspects" 124 : 347-353, 2012

15 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" 68 : 394-424, 2018

16 Zhang S, "Frequencies of BRCA1 and BRCA2 mutations among 1, 342unselected patients with invasive ovarian cancer" 121 : 353-357, 2011

17 Schonfeld SJ, "Declining second primary ovarian cancer after first primary breast cancer" 31 : 738-743, 2013

18 Berkowitz Z, "Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer" 35 : 112-119, 2011

19 Son BH, "Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years" 141 : 155-160, 2006

20 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017" 대한암학회 52 (52): 335-350, 2020

21 강상율, "Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry" 한국유방암학회 23 (23): 115-128, 2020

22 Pal T, "BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases" 104 : 2807-2816, 2005

23 Bolton KL, "Association between BRCA1 and BRCA2mutations and survival in women with invasive epithelial ovarian cancer" 307 : 382-390, 2012